Abstract:
Objective This study aimed to observe the ability of interleukin-15(IL-15) or interleukin-2(IL-2) to act as a potent adjuvant for a dendritic cell(DCs)–directed vaccine strategy to activate T-cell responses in vitro.
Methods Splenic lymphocytes from na ve mice were prepared.Then, bone marrow-derived DCs(BMDCs) were pulsed with tumor antigens and cultured with the splenocytes in the presence of IL-15 or IL-2 for 7 days.The activated T lymphocytes were examined by flow cytometric analysis, interferon-enzyme-linked immunospot, and cytotoxicity assays.
Results IL-15 resulted in an augmentation of T-cell responses following immunizations with BMDCs.The enhanced response was based on the phenotype characteristics of the lymphocytes and their functions.
Conclusion IL-15 may act as a potent adjuvant for the DC-directed vaccine strategy.